Endoscopic follow-up showed similar gastritis recovery rates between supplemented and nonsupplemented groups (80.0% versus 77.3%), with a nonsignificant trend toward shorter median recovery in the supplemented group (9.3 weeks versus 21.9 weeks).
← all excerpts
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer.
2
—
—
The sentences
pylori infection tended to exhibit a higher incidence of zolbetuximab-associated gastritis compared with infected patients (100% versus 84.6%, P = 0.163), although the difference did not reach statistical significance.